365telugu.com online news,september 1st 2025:India’s pharmaceutical sector continues to assert itself as a powerhouse of growth, outperforming the country’s broader economic expansion. In Q1 FY26, while India’s GDP grew by 7.8%, the pharma sector delivered ~11% growth in both revenue and EBITDA, driven by strong performance in hospitals, diagnostics, and export markets.
This double-digit growth underscores the industry’s resilience and its role as a dynamic growth engine in the Indian economy. By leveraging decades of innovation and manufacturing excellence, India has not only cemented its position in the global generics market but also strengthened its role in APIs and biosimilars.
Key Highlights:
- The industry is capitalizing on strengths in generic drugs, APIs, and biosimilars to sustain steady growth.
- Pharma exports remain the backbone of the sector, showcasing India’s global manufacturing capabilities and leadership in affordable healthcare.
- Indian generics dominate global supply, contributing to 40% of worldwide generic sales and commanding over 90% share in HIV and oncology drugs.
- In FY25, pharma exports rose 10% YoY, with the U.S. accounting for 25% of total exports.
- API exports to China and Europe are witnessing strong momentum, reinforcing India as a cost-effective, high-quality production hub.
Commenting on the sector’s performance, Mr. Namit Joshi, Chairman of Pharmexcil, said:
“As India’s GDP continues its robust growth, the pharmaceutical sector has proven to be a high-velocity engine, outperforming broader economic trends. The sector’s strength across domestic and export markets reinforces India’s status as a global healthcare leader, particularly in generics, APIs, and biosimilars.”
With its continued dominance in generics, biosimilars, and APIs, India’s pharmaceutical industry is on track to touch USD 50 billion in exports by FY2030, further strengthening the nation’s economic story.